Arbutus Biopharma Corp.
- ABUS · Nasdaq
- Pharmaceutical Preparations
- Warminster, PA
- 19 employees
- CIK 0001447028
Updated from SEC filings through
Top things to know
Executives
-
Lindsay Androski President and CEO 4, 2026-09-23 -
Tuan Nguyen Chief Financial Officer 4, 2026-09-23
What leadership is saying
“This has been an exciting quarter for our imdusiran development program”
Earnings press release (8-K Ex. 99.1), filed August 12, 2026
Arbutus Biopharma Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Warminster, PA. It trades as ABUS on Nasdaq. Revenue was $14.1M in the fiscal year ending December 31, 2025, +128.2% from the year before. It reported about 19 employees. Lindsay Androski is President and CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $14.1M 10-K, 2026-03-23 | $6.2M 10-K, 2026-03-23 | $18.1M 10-K, 2025-03-27 | $39.0M 10-K, 2024-03-05 | $11.0M 10-K, 2023-03-02 |
| Operating income | -$38.2M 10-K, 2026-03-23 | -$76.3M 10-K, 2026-03-23 | -$78.1M 10-K, 2025-03-27 | -$65.5M 10-K, 2024-03-05 | -$73.5M 10-K, 2023-03-02 |
| SG&A | $15.9M 10-K, 2026-03-23 | $22.1M 10-K, 2026-03-23 | $22.5M 10-K, 2025-03-27 | $17.8M 10-K, 2024-03-05 | $17.1M 10-K, 2023-03-02 |
| Net income | -$33.5M 10-K, 2026-03-23 | -$69.9M 10-K, 2026-03-23 | -$72.8M 10-K, 2025-03-27 | -$69.5M 10-K, 2024-03-05 | -$76.2M 10-K, 2023-03-02 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Lindsay Androski Public Company CEO | experienced Director and Board Chair | former Federal Prosecutor | President and CEO | 4, 2026-09-23 |
| Tuan Nguyen | Chief Financial Officer | 4, 2026-09-23 |
| Joseph Bishop | Board member (per proxy) bio: Director | DEF 14A, 2026-04-14 |
| Matthew Gline | Board member (per proxy) bio: Director | DEF 14A, 2026-04-14 |
| Robert Alan Beardsley | Board member (per proxy) bio: Director | DEF 14A, 2026-04-14 |
| Roger Sawhney | Board member (per proxy) bio: Director | DEF 14A, 2026-04-14 |
| Anuj Hasija | our Board | 10-K, 2026-03-23 |
What Arbutus Biopharma Corp does
Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV).
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 197.8 million (as of August 10, 2026) | 10-Q, August 12, 2026 |
|---|---|---|
| Public float | $472M (as of June 30, 2025) | 10-K, March 23, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 12, 2026 |
| Latest proxy statement | Meeting May 26, 2026 (filed April 14, 2026) | DEF 14A, April 14, 2026 |
| Auditor | Ernst & Young LLP (Philadelphia, Pennsylvania) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-10-22
- Item 8.01 Other events
- 8-K filed 2026-08-21
- Item 8.01 Other events
- 8-K filed 2026-08-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-16
- Item 1.02 Termination of a material definitive agreement
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 8.01 Other events
- 8-K filed 2026-05-27
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-15
- Item 8.01 Other events
- 8-K filed 2026-03-23
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-03
- Item 1.01 Entry into a material definitive agreement
- Item 8.01 Other events
- 8-K filed 2026-02-20
- Item 8.01 Other events
Frequently asked questions about Arbutus Biopharma Corp
- What does Arbutus Biopharma Corp do?
- In its own words, from Item 1 of its 10-K: "Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV)."
- What is Arbutus Biopharma Corp's revenue?
- $14.1M for the fiscal year ending December 31, 2025, from its 10-K filed March 23, 2026.
- Is Arbutus Biopharma Corp profitable?
- Arbutus Biopharma Corp reported net income of -$33.5M for the fiscal year ending December 31, 2025.
- How many employees does Arbutus Biopharma Corp have?
- About 19 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Arbutus Biopharma Corp?
- Lindsay Androski, President and CEO, as named in a 4 filed September 23, 2026.
- Who is the CFO of Arbutus Biopharma Corp?
- Tuan Nguyen, Chief Financial Officer, as named in a 4 filed September 23, 2026.
- Where is Arbutus Biopharma Corp headquartered?
- Warminster, PA.
- What is Arbutus Biopharma Corp's stock ticker?
- ABUS on Nasdaq.
- What industry is Arbutus Biopharma Corp in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Arbutus Biopharma Corp's website?
- arbutusbio.com.
- When does Arbutus Biopharma Corp report earnings next?
- November 12, 2026. Source: pg_future_events.
- Is Arbutus Biopharma Corp a public company?
- Yes. Arbutus Biopharma Corp files with the SEC under CIK 0001447028 and trades as ABUS.
- Who audits Arbutus Biopharma Corp?
- Ernst & Young LLP, Philadelphia, Pennsylvania, as named in its latest annual report (10-K).
- How many shares of Arbutus Biopharma Corp are outstanding?
- 197.8 million shares as of August 10, 2026, from its 10-Q filed August 12, 2026.
- What is Arbutus Biopharma Corp's public float?
- $472M as of June 30, 2025, as reported on the cover of its 10-K filed March 23, 2026.
- How many business segments does Arbutus Biopharma Corp report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 12, 2026.
- When is Arbutus Biopharma Corp's annual shareholder meeting?
- May 26, 2026, per its proxy statement (DEF 14A) filed April 14, 2026.